Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance
about
Apolipoprotein C3 gene variants in nonalcoholic fatty liver diseaseDoes Diacylglycerol Accumulation in Fatty Liver Disease Cause Hepatic Insulin Resistance?Pathway-selective insulin resistance and metabolic disease: the importance of nutrient fluxFunctional and topological analysis of yeast acyl-CoA:diacylglycerol acyltransferase 2, an endoplasmic reticulum enzyme essential for triacylglycerol biosynthesisConversion of low density lipoprotein-associated phosphatidylcholine to triacylglycerol by primary hepatocytesMechanisms for insulin resistance: common threads and missing linksMangiferin modulation of metabolism and metabolic syndrome.Glycerolipid signals alter mTOR complex 2 (mTORC2) to diminish insulin signaling.Increased subcutaneous adipose tissue expression of genes involved in glycerolipid-fatty acid cycling in obese insulin-resistant versus -sensitive individualsPathogenesis of non-alcoholic fatty liver disease.Abrogating monoacylglycerol acyltransferase activity in liver improves glucose tolerance and hepatic insulin signaling in obese mice.Effect of diacylglycerol acyltransferase 2 overexpression in 3T3-L1 is associated to an increase in mono-unsaturated fatty acid accumulation.Lipid oversupply, selective insulin resistance, and lipotoxicity: molecular mechanismsGlycerol-3-phosphate acyltransferase 1 deficiency in ob/ob mice diminishes hepatic steatosis but does not protect against insulin resistance or obesity.Intestine-specific expression of acyl CoA:diacylglycerol acyltransferase 1 reverses resistance to diet-induced hepatic steatosis and obesity in Dgat1-/- miceNon-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations.Identification and validation of the pathways and functions regulated by the orphan nuclear receptor, ROR alpha1, in skeletal muscle.Non-high-density lipoprotein cholesterol (non-HDL-C) levels in children with nonalcoholic fatty liver disease (NAFLD)Diacylglycerol-mediated insulin resistance.Foxa1 reduces lipid accumulation in human hepatocytes and is down-regulated in nonalcoholic fatty liver.Involvement and mechanism of DGAT2 upregulation in the pathogenesis of alcoholic fatty liver disease.Hepatic long-chain acyl-CoA synthetase 5 mediates fatty acid channeling between anabolic and catabolic pathways.High-content assays for evaluating cellular and hepatic diacylglycerol acyltransferase activity.A high-fat, ketogenic diet causes hepatic insulin resistance in mice, despite increasing energy expenditure and preventing weight gainCellular mechanisms by which FGF21 improves insulin sensitivity in male miceSerum amylase levels are decreased in Chinese non-alcoholic fatty liver disease patientsAnthropometric and biochemical characteristics of patients with nonalcoholic fatty liver diagnosed by non-invasive diagnostic methodsAbrogation of growth hormone secretion rescues fatty liver in mice with hepatocyte-specific deletion of JAK2.Hepatic insulin resistance in mice with hepatic overexpression of diacylglycerol acyltransferase 2Thematic review series: glycerolipids. DGAT enzymes and triacylglycerol biosynthesis.Peripheral reduction of FGFR4 with antisense oligonucleotides increases metabolic rate and lowers adiposity in diet-induced obese mice.Specific role for acyl CoA:Diacylglycerol acyltransferase 1 (Dgat1) in hepatic steatosis due to exogenous fatty acids.Selective suppression of adipose tissue apoE expression impacts systemic metabolic phenotype and adipose tissue inflammation.The role of peroxisome proliferator-activated receptor gamma coactivator-1 beta in the pathogenesis of fructose-induced insulin resistance.Liver-specific loss of lipin-1-mediated phosphatidic acid phosphatase activity does not mitigate intrahepatic TG accumulation in miceHepatitis C virus core protein decreases lipid droplet turnover: a mechanism for core-induced steatosis.Dissociation of inositol-requiring enzyme (IRE1α)-mediated c-Jun N-terminal kinase activation from hepatic insulin resistance in conditional X-box-binding protein-1 (XBP1) knock-out mice.Treatment of rats with Jiangzhi Capsule improves liquid fructose-induced fatty liver: modulation of hepatic expression of SREBP-1c and DGAT-2.DGAT1 deficiency decreases PPAR expression and does not lead to lipotoxicity in cardiac and skeletal muscle.The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes
P2860
Q24611284-A6F09E20-41A7-4B03-834D-8015AA07AF12Q26798161-044531D1-7DA4-41DE-8006-DEB1813EED16Q26820876-CB3F473D-616C-457D-91A5-5D8151C44FCAQ27938569-05CFB1A9-81B8-4F89-A812-573CBDB583F3Q28506881-1B1C8DA0-EE30-47C1-B8FB-976296FC5977Q29620447-D434741B-E1FB-41E3-9107-3C2166214800Q30244206-31A4BD57-E6FF-47E2-AD2A-78EF7BADFC5DQ30425815-92064A7D-2DA9-47D8-88A5-2A4FF3D9427CQ33570114-1EE72272-187C-4FCE-B031-B28F3A90C937Q33606303-11E7A8AB-1418-4CAA-9149-8AA049DA33F6Q33789323-4FBCE80F-1D54-417C-B6E8-1E30E506F8CAQ33824420-B1937D85-9F01-474E-A6CC-F1370059863BQ33843550-8E3BA03A-2194-4350-A156-3C05036032ABQ33869725-CAC83C11-86D3-4DEF-A986-2DA945059126Q33902090-96FCC980-98CB-4F86-AB60-BC2E52EA2CE7Q33948324-76BB964C-3092-4A50-ABDA-FE1EC1D900C0Q34020241-74530E05-13E5-479C-9E23-4A0539A48F55Q34037347-958B384F-16F7-41E2-B2B5-5199BBA439CCQ34109119-02A6473F-AA42-49B2-9B19-AD95626D3315Q34125393-D3011253-CCD8-4C0E-8063-7211D2487650Q34187979-0014112E-A520-4991-ACBC-FC9D5AD1754EQ34188050-0DDA377A-EF20-4D28-A2CF-680F720EE127Q34287889-B9CBEB00-5463-43DC-9F60-DA532B92479DQ34305197-944439D5-2A9C-41B2-81F9-804A018923C0Q34350772-19F2A415-02F1-45CA-B9E9-B2E02244479EQ34709831-D89192B9-734F-4D92-A5AC-0DB06D756A54Q34746071-3CBBD36E-AD49-4BA4-8E1C-28D5E7454ADBQ34755080-1CDDC85C-074C-401F-AE41-EF0CDB6411D1Q34804981-0676D37E-CEA9-4459-9163-437B2C902C43Q34817393-33A1CB93-2DE5-43B2-8E7A-8A6D8D9322F4Q34901544-A861F434-5699-49B4-BD7A-1032F2DDA11CQ34989773-C80C74FB-0561-4E7B-AB79-3557ACE52230Q35014212-04FF4E7A-8923-4C2B-98C7-665BC5FFD932Q35090215-3E7B542A-4CAE-4FC2-BAA9-7A93E7254075Q35217044-F1D98D35-5DD2-49ED-9B3A-0A74B4EF1DF4Q35604983-7BE1CE73-9BFA-42FF-A0AC-45B15942F8DBQ35709954-FA2A093C-4D8D-4998-9FB2-9E99D8E15525Q35743140-24A67E4C-BCC3-466F-9A2E-C8742874FAF5Q35771152-44771A20-634D-4CEC-B491-A303A699DD36Q35811523-5D342C61-CED3-4533-B17A-A3952EE1755F
P2860
Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance
description
2007 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
article publié dans la revue scientifique Journal of Biological Chemistry
@fr
artículu científicu espublizáu en 2007
@ast
im August 2007 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2007/08/03)
@sk
vědecký článek publikovaný v roce 2007
@cs
wetenschappelijk artikel (gepubliceerd op 2007/08/03)
@nl
наукова стаття, опублікована в серпні 2007
@uk
name
Suppression of diacylglycerol ...... eatosis and insulin resistance
@ast
Suppression of diacylglycerol ...... eatosis and insulin resistance
@en
Suppression of diacylglycerol ...... eatosis and insulin resistance
@nl
type
label
Suppression of diacylglycerol ...... eatosis and insulin resistance
@ast
Suppression of diacylglycerol ...... eatosis and insulin resistance
@en
Suppression of diacylglycerol ...... eatosis and insulin resistance
@nl
prefLabel
Suppression of diacylglycerol ...... eatosis and insulin resistance
@ast
Suppression of diacylglycerol ...... eatosis and insulin resistance
@en
Suppression of diacylglycerol ...... eatosis and insulin resistance
@nl
P2093
P50
P3181
P356
P1476
Suppression of diacylglycerol ...... eatosis and insulin resistance
@en
P2093
Alberto Distefano
Ameya Kulkarni
Brett P. Monia
Cheol Soo Choi
Dongyan Zhang
Gary W. Cline
John G. Geisler
Mario Kahn
Sanjay Bhanot
P304
22678–22688
P3181
P356
10.1074/JBC.M704213200
P407
P577
2007-08-03T00:00:00Z